azacitidine has been researched along with Cancer of the Urinary Tract in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chai, CY; Chen, WT; Huang, YC; Hung, WC; Jiang, WH; Yu, HS | 1 |
| Alva, AS; Aparicio, AM; Hahn, NM; Singal, R; Sonpavde, G; Yellapragada, S | 1 |
1 review(s) available for azacitidine and Cancer of the Urinary Tract
| Article | Year |
|---|---|
Hypomethylating agents for urologic cancers.
Topics: Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Humans; Treatment Outcome; Urologic Neoplasms | 2011 |
1 other study(ies) available for azacitidine and Cancer of the Urinary Tract
| Article | Year |
|---|---|
Effects of MEK and DNMT inhibitors on arsenic-treated human uroepithelial cells in relation to Cyclin-D1 and p16.
Topics: Arsenic Poisoning; Arsenites; Azacitidine; Blotting, Western; Butadienes; Cell Cycle; Cells, Cultured; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Modification Methylases; Dose-Response Relationship, Drug; Environmental Exposure; Humans; MAP Kinase Kinase Kinases; Neoplasm Proteins; Nitriles; Reverse Transcriptase Polymerase Chain Reaction; Urologic Neoplasms; Urothelium | 2011 |